NAFDAC: No herbal medicine approved for the treatment of COVID


The National Agency for Food and Drug Administration and Control (NAFDAC) says it has not approved any herbal medicines for the treatment of COVID-19.

This was revealed in a statement issued on Sunday by NAFDAC spokesperson Olusayo Akintola.

The statement quotes Mojisola Adeyeye, chief executive of NAFDAC, as saying that “no medicine has yet been found to cure COVID-19.”

She said any product without NAFDAC approval for the treatment of COVID-19 is null and void, adding that anyone claiming otherwise violates the protocol of national regulatory authorities.

Citing herbal medicine developed by the University of Jos for the treatment of COVID-19, she said the agency had warned the institution that it could not claim to have found a cure for the virus unless the product had gone through the registration process of NAFDAC.

“They were trying to sell it to their staff. It is a violation of our own regulatory policies,” she said.

“No one should say this one can cure this or that without going through the NAFDAC registration process. Herbal medicine research by academia is normal.

“It is now up to academia to also recognize the national regulatory authority established to protect the safety of the Nigerian people, ensuring that the product they are working on must pass through NAFDAC.”

Adeyeye said although there are herbal medicines that could alleviate the symptoms of COVID-19, NAFDAC has not granted any drug approval for treatment.

“NAFDAC Approves Listing of These Drugs; this means that it has been tested and found to be safe to use. NAFDAC cannot say herbal medicine can treat COVID-19 until clinical trials are complete,” she said.

“At present, no herbal medicine has gone through full clinical trials in the way clinical trials are supposed to be done.”

She said that to do a formal clinical trial, you have to develop a protocol, which has to go through the National Health Research Ethics Committee (NHREC), after which it will go through NAFDAC.


Comments are closed.